Literature DB >> 33902636

Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.

Guanyi Wang1, Yibin Jia1, Yuqin Ye1,2, Enming Kang1, Huijun Chen1, Jiayou Wang1, Xiaosheng He3.   

Abstract

BACKGROUND: Posterior fossa ependymoma (EPN-PF) can be classified into Group A posterior fossa ependymoma (EPN-PFA) and Group B posterior fossa ependymoma (EPN-PFB) according to DNA CpG island methylation profile status and gene expression. EPN-PFA usually occurs in children younger than 5 years and has a poor prognosis.
METHODS: Using epigenome and transcriptome microarray data, a multi-component weighted gene co-expression network analysis (WGCNA) was used to systematically identify the hub genes of EPN-PF. We downloaded two microarray datasets (GSE66354 and GSE114523) from the Gene Expression Omnibus (GEO) database. The Limma R package was used to identify differentially expressed genes (DEGs), and ChAMP R was used to analyze the differential methylation genes (DMGs) between EPN-PFA and EPN-PFB. GO and KEGG enrichment analyses were performed using the Metascape database.
RESULTS: GO analysis showed that enriched genes were significantly enriched in the extracellular matrix organization, adaptive immune response, membrane raft, focal adhesion, NF-kappa B pathway, and axon guidance, as suggested by KEGG analysis. Through WGCNA, we found that MEblue had a significant correlation with EPN-PF (R = 0.69, P = 1 × 10-08) and selected the 180 hub genes in the blue module. By comparing the DEGs, DMGs, and hub genes in the co-expression network, we identified five hypermethylated, lower expressed genes in EPN-PFA (ATP4B, CCDC151, DMKN, SCN4B, and TUBA4B), and three of them were confirmed by IHC.
CONCLUSION: ssGSEA and GSVA analysis indicated that these five hub genes could lead to poor prognosis by inducing hypoxia, PI3K-Akt-mTOR, and TNFα-NFKB pathways. Further study of these dysmethylated hub genes in EPN-PF and the pathways they participate in may provides new ideas for EPN-PF treatment.

Entities:  

Keywords:  Differential genes; Epigenome; Posterior fossa ependymoma; Transcriptome; WGCNA

Year:  2021        PMID: 33902636     DOI: 10.1186/s12967-021-02834-1

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  50 in total

1.  Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.

Authors:  Ruman Rahman; Teresa Osteso-Ibanez; Robert A Hirst; Jane Levesley; John-Paul Kilday; Siobhan Quinn; Andrew Peet; Chris O'Callaghan; Beth Coyle; Richard G Grundy
Journal:  Mol Cancer Ther       Date:  2010-07-19       Impact factor: 6.261

2.  Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.

Authors:  Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti
Journal:  Acta Neuropathol       Date:  2017-07-21       Impact factor: 17.088

Review 3.  Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries.

Authors:  Patompon Wongtrakoongate
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

4.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.

Authors:  Kristian W Pajtler; Hendrik Witt; Martin Sill; David T W Jones; Volker Hovestadt; Fabian Kratochwil; Khalida Wani; Ruth Tatevossian; Chandanamali Punchihewa; Pascal Johann; Jüri Reimand; Hans-Jörg Warnatz; Marina Ryzhova; Steve Mack; Vijay Ramaswamy; David Capper; Leonille Schweizer; Laura Sieber; Andrea Wittmann; Zhiqin Huang; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Daniel Fults; Helen Toledano; Smadar Avigad; Lindsey M Hoffman; Andrew M Donson; Nicholas Foreman; Ekkehard Hewer; Karel Zitterbart; Mark Gilbert; Terri S Armstrong; Nalin Gupta; Jeffrey C Allen; Matthias A Karajannis; David Zagzag; Martin Hasselblatt; Andreas E Kulozik; Olaf Witt; V Peter Collins; Katja von Hoff; Stefan Rutkowski; Torsten Pietsch; Gary Bader; Marie-Laure Yaspo; Andreas von Deimling; Peter Lichter; Michael D Taylor; Richard Gilbertson; David W Ellison; Kenneth Aldape; Andrey Korshunov; Marcel Kool; Stefan M Pfister
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

5.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

6.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.

Authors:  S C Mack; H Witt; R M Piro; L Gu; S Zuyderduyn; A M Stütz; X Wang; M Gallo; L Garzia; K Zayne; X Zhang; V Ramaswamy; N Jäger; D T W Jones; M Sill; T J Pugh; M Ryzhova; K M Wani; D J H Shih; R Head; M Remke; S D Bailey; T Zichner; C C Faria; M Barszczyk; S Stark; H Seker-Cin; S Hutter; P Johann; S Bender; V Hovestadt; T Tzaridis; A M Dubuc; P A Northcott; J Peacock; K C Bertrand; S Agnihotri; F M G Cavalli; I Clarke; K Nethery-Brokx; C L Creasy; S K Verma; J Koster; X Wu; Y Yao; T Milde; P Sin-Chan; J Zuccaro; L Lau; S Pereira; P Castelo-Branco; M Hirst; M A Marra; S S Roberts; D Fults; L Massimi; Y J Cho; T Van Meter; W Grajkowska; B Lach; A E Kulozik; A von Deimling; O Witt; S W Scherer; X Fan; K M Muraszko; M Kool; S L Pomeroy; N Gupta; J Phillips; A Huang; U Tabori; C Hawkins; D Malkin; P N Kongkham; W A Weiss; N Jabado; J T Rutka; E Bouffet; J O Korbel; M Lupien; K D Aldape; G D Bader; R Eils; P Lichter; P B Dirks; S M Pfister; A Korshunov; M D Taylor
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962

Review 7.  Ependymoma.

Authors:  Elizabeth R Gerstner; Kristian W Pajtler
Journal:  Semin Neurol       Date:  2018-03-16       Impact factor: 3.420

8.  Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial.

Authors:  David I Sandberg; Bangning Yu; Rajan Patel; John Hagan; Emilie Miesner; Jennifer Sabin; Sarah Smith; Stephen Fletcher; Manish N Shah; Rachael W Sirianni; Michael D Taylor
Journal:  J Neurooncol       Date:  2018-11-20       Impact factor: 4.130

9.  Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma.

Authors:  Hazel Anne Rogers; Rebecca Chapman; Holly Kings; Julie Allard; Jodie Barron-Hastings; Kristian W Pajtler; Martin Sill; Stefan Pfister; Richard Guy Grundy
Journal:  Oncotarget       Date:  2018-11-23

10.  PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.

Authors:  Siddhant U Jain; Truman J Do; Peder J Lund; Andrew Q Rashoff; Katharine L Diehl; Marcin Cieslik; Andrea Bajic; Nikoleta Juretic; Shriya Deshmukh; Sriram Venneti; Tom W Muir; Benjamin A Garcia; Nada Jabado; Peter W Lewis
Journal:  Nat Commun       Date:  2019-05-13       Impact factor: 14.919

View more
  3 in total

Review 1.  The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know.

Authors:  A G Osborn; D N Louis; T Y Poussaint; L L Linscott; K L Salzman
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-16       Impact factor: 4.966

Review 2.  Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours.

Authors:  Cristina Ferreras; Lucía Fernández; Laura Clares-Villa; Marta Ibáñez-Navarro; Carla Martín-Cortázar; Isabel Esteban-Rodríguez; Javier Saceda; Antonio Pérez-Martínez
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

3.  Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.

Authors:  Jonas E Adolph; Gudrun Fleischhack; Christine Gaab; Ruth Mikasch; Martin Mynarek; Stefan Rutkowski; Ulrich Schüller; Stefan M Pfister; Kristian W Pajtler; Till Milde; Olaf Witt; Brigitte Bison; Monika Warmuth-Metz; Rolf-Dieter Kortmann; Stefan Dietzsch; Torsten Pietsch; Beate Timmermann; Stephan Tippelt
Journal:  J Neurooncol       Date:  2021-10-16       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.